吉西他滨和奥沙利铂联合阿帕替尼治疗晚期卵巢癌患者的疗效分析

doi:10.3760/cma.j.cn441417-20241225-11028

摘要/Abstract

摘要：

目的　分析吉西他滨和奥沙利铂联合阿帕替尼治疗方案对晚期卵巢癌患者血清肿瘤标志物及预后的影响。方法　回顾性选取2022年2月至2024年2月南阳市中心医院收治的晚期卵巢癌患者76例，按照治疗方法不同分为对照组和观察组，每组38例。对照组年龄（51.27±3.28）岁，病理分期：Ⅲ期16例、Ⅳ期22例；采用吉西他滨和奥沙利铂治疗，第1、8天予以吉西他滨1 000 mg/m2，静脉滴注；第1天予以奥沙利铂130 mg/m2，静脉滴注。连续治疗3周为1个疗程。观察组年龄（50.92±3.35）岁，病理分期：Ⅲ期18例、Ⅳ期20例；在对照组基础上联合阿帕替尼治疗，口服，500 mg/次，1次/d；持续服用14 d后，如无严重不良反应，调整剂量至750 mg/次，直至病情进展或者无法耐受。两组患者均连续治疗3个疗程。对比两组临床疗效、肿瘤标志物［糖类抗原125（CA125）、癌胚抗原（CEA）、细胞角蛋白19片段抗原21-1（CYFRA21-1）］、血管内皮生长因子受体（VEGFR）、血小板源性生长因子受体（PDGFR）、炎症因子［白细胞介素-6（IL-6）、IL-10、干扰素-γ（INF-γ）］水平和中国癌症患者化学生物治疗生活质量量表（QLQ-CCC）评分、不良反应。采用χ2检验、t检验进行统计分析。结果　观察组患者的疾病控制率高于对照组［84.21%（32/38）比63.16%（24/38）］，差异有统计学意义（χ2=4.343，P=0.037）。治疗3个疗程后，观察组的CA125、CEA、CYFRA21-1、VEGFR、PDGFR、IL-6、IL-10、INF-γ水平分别为（31.54±2.05）U/ml、（2.46±0.52）ng/L、（15.87±1.26）g/L、（408.56±70.45）ng/L、（64.62±4.28）ng/L、（1.24±0.25）mg/L、（1.38±0.27）mg/L、（13.48±1.54）mg/L，对照组上述指标分别为（52.68±2.37）U/ml、（4.57±0.76）ng/L、（26.84±1.45）g/L、（495.27±80.23）ng/L、（72.51±5.17）ng/L、（3.27±0.43）mg/L、（3.45±0.38）mg/L、（7.02±0.92）mg/L，差异均有统计学意义（均P<0.05）；观察组QLQ-CCC的生理、社会、心理、总体感觉评分均高于对照组（均P<0.05）。两组不良反应总发生率差异无统计学意义（P>0.05）。结论　吉西他滨和奥沙利铂联合阿帕替尼治疗晚期卵巢癌患者，可提高疾病控制率，降低肿瘤标志物水平，抑制炎症因子释放，改善预后，提高生存质量。

关键词: 卵巢癌, 吉西他滨, 奥沙利铂, 阿帕替尼, 疗效, 生存质量

Abstract:

Objective　To retrospectively analyze the effects of apatinib combined with gemcitabine plus oxaliplatin regimen on serum tumor markers and prognosis of patients with advanced ovarian cancer. Methods　A total of 76 patients with advanced ovarian cancer admitted to Nanyang Central Hospital from February 2022 to February 2024 were retrospectively selected and divided into control group and observation group according to different treatment methods, with 38 cases in each group. The age of control group was (51.27±3.28) years old, with pathological staging of 16 cases in stage III and 22 cases in stage IV; they received treatment with gemcitabine and oxaliplatin, with gemcitabine administered intravenously at a dose of 1,000 mg/m² on days 1 and 8, and oxaliplatin at a dose of 130 mg/m² on day 1. Continuous treatment for 3 weeks constituted one cycle. The age of the observation group was ((50.92±3.35) years old, with 18 cases in stage III and 20 cases in stage IV; they received apatinib in addition to the treatment in the control group, orally at a dose of 500 mg once daily. After 14 days of continuous use without severe adverse reactions, the dose was adjusted to 750 mg once daily until disease progression or intolerance occurred. Both groups underwent a total of 3 treatment cycles. Clinical efficacy, tumor markers [carbohydrate antigen (CA125), carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1)], vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), inflammatory factors [interleukin-6 (IL-6), IL-10, interferon-γ (INF-γ)] levels, the Chinese Cancer Patient Chemotherapy Quality of Life Scale (QLQ-CCC) scores, and adverse reactions were compared between the two groups. Statistical analysis was performed using χ² tests and t tests. Results　The disease control rate in the observation group was higher than that in the control group [84.21% (32/38) vs. 63.16% (24/38)], with a statistically significant difference (χ²=4.343, P=0.037). After three treatment cycles, the levels of CA125, CEA, CYFRA21-1, VEGFR, PDGFR, IL-6, IL-10, and INF-γ in the observation group were (31.54±2.05) U/ml, (2.46±0.52) ng/L, (15.87±1.26) g/L, (408.56±70.45) ng/L, (64.62±4.28) ng/L, (1.24±0.25) mg/L, and (1.38±0.27) mg/L, (13.48±1.54)mg/L, respectively, compared to (52.68±2.37) U/ml, (4.57±0.76) ng/L, (26.84±1.45) g/L, (495.27±80.23) ng/L, (72.51±5.17) ng/L, (3.27±0.43) mg/L, (3.45±0.38) mg/L, and(7.02±0.92)mg/L in the control group, with all differences being statistically significant (all P<0.05). The QLQ-CCC scores for physiological, social, psychological, and overall sensation in the observation group were all higher than those in the control group (all P<0.05). The overall incidence of adverse reactions between the two groups was not statistically significant (P>0.05). Conclusion　Apatinib combined with gemcitabine plus oxaliplatin regimen in patients with advanced ovarian cancer can improve the disease control rate, reduce tumor marker levels, inhibit the release of inflammatory factors, improve prognosis, and enhance quality of life in patients with advanced ovarian cancer.

Key words: Ovarian cancer, , Gemcitabine, , Oxaliplatin, , Apatinib, , Efficacy, , Quality of life

刘子龙付小玲张欣. 吉西他滨和奥沙利铂联合阿帕替尼治疗晚期卵巢癌患者的疗效分析 [J]. 国际医药卫生导报, 2025, 31(11): 1911-1915.

Liu Zilong, Fu Xiaoling, Zhang Xin.

Effect of apatinib combined with gemcitabine plus oxaliplatin regimen on serum tumor markers and prognosis in patients with advanced ovarian cancer [J]. International Medicine and Health Guidance News, 2025, 31(11): 1911-1915.

参考文献

[1]鲁佩佩,辛文秀.龙葵当归三棱汤治疗卵巢癌临床疗效及对免疫指标及炎性因子的影响[J].中华中医药学刊,2020,38(3):242-245. DOI:10.13193/j.issn.1673-7717.2020.03.064.

[2]宋亭亭,刘国燕,王言研,等.桂枝茯苓汤对卵巢癌术后化疗的增敏效果及对炎症因子和免疫指标的影响[J].中华中医药学刊,2021,39(5):251-254. DOI:10.13193/j.issn.1673-7717.2021.05.061.

[3]冉霞,刘晓娟.阿帕替尼联合GEMOX方案晚期难治性卵巢癌疗效及安全性评价[J].中国性科学,2020,29(1):44-48. DOI:10.3969/j.issn.1672-1993.2020.01.014.

[4]刘锦,张敏,王卉,等.紫杉醇脂质体联合顺铂治疗晚期卵巢癌患者的疗效及血清肿瘤标志物水平分析[J].国际医药卫生导报,2022,28(23):3260-3263. DOI:10.3760/cma.j.issn.1007-1245.2022.23.002.

[5]马韬,何昌玉,蒋金玲,等.吉西他滨联合奥沙利铂与吉西他滨单药辅助治疗体力状态良好的可切除胰腺癌的比较[J].内科理论与实践,2018,13(3):158-164. DOI:10.16138/j.1673-6087.2018.03.006.

[6]邵霞,丁耘峰,王战伟.奥沙利铂注射液联合紫杉醇注射液和吉西他滨注射液治疗晚期三阴乳腺癌的临床研究[J].中国临床药理学杂志,2018,34(11):1302-1305.DOI:10.13699/j.cnki.1001-6821.2018.11.012.

[7]常英英,郭克锋,王坤,等.阿帕替尼联合NP化疗治疗晚期非小细胞肺癌疗效及对患者血清肿瘤标志物和生存质量的影响[J].中国药师,2019,22(10):1868-1870. DOI:10.3969/j.issn.1008-049X.2019.10.022.

[8]谢心弦.阿帕替尼联合新辅助化疗治疗晚期卵巢癌疗效及对PI3K/AKT/mTOR信号通路的影响[J].生命科学仪器,2023,21(3):后插10.

[9]国家癌症中心,国家肿瘤质控中心卵巢癌质控专家委员会.中国卵巢癌规范诊疗质量控制指标(2022版)[J].中华肿瘤杂志,2022,44(7):609-614. DOI:10.3760/cma.j.cn112152-20220418-00268.

[10]冯奉仪.实体瘤新的疗效评价标准(解读1.1版RECIST标准)[C]//第三届中国肿瘤内科大会论文集. 2009:123-125.

[11]李建娣,俞维英.黄芪注射液辅助治疗对卵巢癌患者的治疗效果及对患者生活质量、炎症因子、T淋巴细胞的影响[J].新中医,2019,51(8):194-196. DOI:10.13457/j.cnki.jncm.2019.08.058.

[12]Yang ST, Chang WH, Chou FW, et al. Front-line chemoimmunotherapy for treating epithelial ovarian cancer: part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen[J]. Taiwan J Obstet Gynecol, 2024, 63(1): 10-16. DOI: 10.1016/j.tjog.2023.11.005.

[13]古力米热·布然江,热孜亚·库尔班,艾力克木·阿不都玩克,等.益气养阴汤联合贝伐珠单抗治疗卵巢癌对患者免疫功能、炎性因子及肿瘤标志物的影响[J].癌症进展,2019,17(7):827-830,858. DOI:10.11877/j.issn.1672-1535.2019.17.07.23.

[14]周能芳.免疫细胞治疗联合化疗治疗晚期卵巢癌患者的疗效及对细胞免疫的影响[J].现代肿瘤医学,2018,26(3):436-440. DOI:10.3969/j.issn.1672-4992.2018.03.028.

[15]张振华,李娟,卢雯平.益气活血解毒方治疗晚期卵巢癌有效可能的单核苷酸多态性位点及基因靶点[J].中国医药,2018,13(4):601-605. DOI:10.3760/cma.j.issn.1673-4777.2018.04.031.

[16]杨庆蕊,王文翔,杨静,等.紫杉醇联合卡铂治疗晚期卵巢癌的临床疗效及对肿瘤标志物和不良反应的影响[J].癌症进展,2023,21(24):2742-2745. DOI:10.11877/j.issn.1672-1535.2023.21.24.18.

[17]周敏,袁渊,朱明,等.注射用紫杉醇脂质体治疗晚期卵巢癌及对患者血清肿瘤标志物和免疫功能的影响[J].中国妇产科临床杂志,2022,23(1):42-45. DOI:10.13390/j.issn.1672-1861.2022.01.013.

[18]黄可上,徐勇飞,祖恩慧.贝伐珠单抗联合TC方案治疗晚期卵巢癌对肿瘤标志物免疫功能及血清学指标的影响[J].中国妇幼保健,2024,39(22):4400-4403. DOI:10.19829/j.zgfybj.issn.1001-4411.2024.22.011.

[19]叶青燕,吴凯,练华珍,等.白蛋白结合型紫杉醇联合卡铂治疗晚期卵巢癌的疗效及不良反应分析[J].临床药物治疗杂志,2024,22(4):52-56. DOI:10.3969/j.issn.1672-3384.2024.04.010.

[20]李长生,袁小笋,冀叶,等.甲磺酸阿帕替尼联合GEMOX方案肝动脉化疗栓塞术对晚期肝细胞癌患者的疗效分析[J].中西医结合肝病杂志,2022,32(2):124-127,130. DOI:10.3969/j.issn.1005-0264.2022.02.007.

[21]褚超男,黄琪.脂质体多柔比星单药与吉西他滨联合奥沙利铂对复发性铂耐药卵巢癌患者的疗效及安全性比较[J].国际肿瘤学杂志,2019,46(1):32-35. DOI:10.3760/cma.j.issn.1673-422X.2019.01.007.

[22]邓洁,董丽丽,杨茂鹏,等.阿帕替尼联合GP方案化学治疗晚期肺癌患者的近期临床效果及对血清肿瘤标志物的影响[J].临床误诊误治,2018,31(8):60-63. DOI:10.3969/j.issn.1002-3429.2018.08.014.

[23]裴晓俊.甲磺酸阿帕替尼联合吉西他滨+顺铂化疗对晚期非小细胞肺癌患者疾病缓解率及卡氏评分的影响[J].中国药物与临床,2020,20(8):1349-1351. DOI:10.11655/zgywylc2020.08.053.

[24]陈少卿,黎军和,余永春,等.吉西他滨联合阿帕替尼二线治疗复发转移性鼻咽癌疗效及安全性分析[J].中华肿瘤防治杂志,2019,26(20):1547-1550. DOI:10.16073/j.cnki.cjcpt.2019.20.10.

[25]王云涛,熊伟杰,徐毅,等.替吉奥联合奥沙利铂治疗老年晚期结肠癌的效果及对血清学指标的影响[J].中国医药,2020,15(2):267-270. DOI:10.3760/j.issn.1673-4777.2020.02.026.

[26]王秀芝,常金,宋丹,等.卡瑞利珠单抗联合阿帕替尼治疗晚期原发性肝癌患者效果研究[J].实用肝脏病杂志,2024,27(4):591-594. DOI:10.3969/j.issn.1672-5069.2024.04.025.